Literature DB >> 30603763

A Novel Prediction Model for Bloodstream Infections in Hepatobiliary-Pancreatic Surgery Patients.

Po-Sheng Yang1,2, Chang-Pan Liu3, Yi-Chiung Hsu4, Chuen-Fei Chen5, Chi-Chan Lee6, Shih-Ping Cheng5,6.   

Abstract

BACKGROUND: Bloodstream infections (BSI) are an important source of postoperative mortality in hepatobiliary-pancreatic surgery (HBPS) patients, and no prediction model has been analyzed before.
METHODS: Using big data from the electronic medical records of the administrative and culture databases of MacKay Memorial Hospital, we identified the potential risk factors for community-acquired and healthcare-associated BSI and mortality of patients who received HBPS. Subsequently, we analyzed the microorganisms' profiles and antimicrobial susceptibility patterns for these BSI.
RESULTS: BSI were found in 6.3% patients (349 of 5513 HBPS patients), and hospital mortality was 1.48% (82 of 5513). Dividing patients into low-, intermediate-, and high-risk groups on the basis of sex, age, status of comorbidity (renal failure, peptic ulcer disease, fluid and electrolyte disorders, and acute cholecystitis), a predictive BSI risk score model was developed. According to this model, BSI risk ranged from 1.43% to 11.95%; AUROC to predict BSI risk was 0.72 (95% CI 0.69-0.75). From this retrospective study, Enterobacteriaceae were the most common microorganisms that were isolated from BSI. For both community-acquired and healthcare-associated BSI, imipenem and colistin are the most successful.
CONCLUSION: This novel model can be useful to predict who is at risk of BSI after HBPS, and new prophylactic protocols for these patients are needed.

Entities:  

Mesh:

Year:  2019        PMID: 30603763     DOI: 10.1007/s00268-018-04903-x

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  30 in total

1.  Tai chi exercise in patients with chronic heart failure: a randomized clinical trial.

Authors:  Gloria Y Yeh; Ellen P McCarthy; Peter M Wayne; Lynne W Stevenson; Malissa J Wood; Daniel Forman; Roger B Davis; Russell S Phillips
Journal:  Arch Intern Med       Date:  2011-04-25

2.  Comorbidity measures for use with administrative data.

Authors:  A Elixhauser; C Steiner; D R Harris; R M Coffey
Journal:  Med Care       Date:  1998-01       Impact factor: 2.983

3.  The Charlson age comorbidity index predicts prognosis in patients with resected pancreatic cancer.

Authors:  Tomonari Asano; Suguru Yamada; Tsutomu Fujii; Norimitsu Yabusaki; Goro Nakayama; Hiroyuki Sugimoto; Masahiko Koike; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Int J Surg       Date:  2017-02-02       Impact factor: 6.071

4.  Mortality and morbidity of hepatectomy, radiofrequency ablation, and embolization for hepatocellular carcinoma: a national survey of 54,145 patients.

Authors:  Masaya Sato; Ryosuke Tateishi; Hideo Yasunaga; Hiromasa Horiguchi; Haruhiko Yoshida; Shinya Matsuda; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2012-03-17       Impact factor: 7.527

5.  Shifting trends in liver-directed management of patients with colorectal liver metastasis: a population-based analysis.

Authors:  Skye C Mayo; Jennifer E Heckman; Andrew D Shore; Hari Nathan; Alexander A Parikh; John F P Bridges; Robert A Anders; Daniel A Anaya; Natasha S Becker; Timothy M Pawlik
Journal:  Surgery       Date:  2011-08       Impact factor: 3.982

6.  CDC definitions for nosocomial infections, 1988.

Authors:  J S Garner; W R Jarvis; T G Emori; T C Horan; J M Hughes
Journal:  Am J Infect Control       Date:  1988-06       Impact factor: 2.918

7.  Poor oncologic outcomes of hepatocellular carcinoma patients with intra-abdominal infection after hepatectomy.

Authors:  Dan-Yun Ruan; Ze-Xiao Lin; Yang Li; Nan Jiang; Xing Li; Dong-Hao Wu; Tian-Tian Wang; Jie Chen; Qu Lin; Xiang-Yuan Wu
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

8.  National trends in the management and survival of surgically managed gallbladder adenocarcinoma over 15 years: a population-based analysis.

Authors:  Skye C Mayo; Andrew D Shore; Hari Nathan; Barish Edil; Christopher L Wolfgang; Kenzo Hirose; Joseph Herman; Richard D Schulick; Michael A Choti; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2010-09-08       Impact factor: 3.452

9.  Antimicrobial susceptibility profiles of Gram-negative bacilli isolated from patients with hepatobiliary infections in Taiwan: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2006-2010.

Authors:  Han-Siong Toh; Yin-Ching Chuang; Chi-Chang Huang; Yu-Lin Lee; Yuag-Meng Liu; Cheng-Mao Ho; Po-Liang Lu; Chun-Eng Liu; Yen-Hsu Chen; Jen-Hsien Wang; Wen-Chien Ko; Kwok-Woon Yu; Yung-Ching Liu; Yao-Shen Chen; Hung-Jen Tang; Po-Ren Hsueh
Journal:  Int J Antimicrob Agents       Date:  2012-06       Impact factor: 5.283

10.  Survival outcomes of hepatocellular carcinoma resection with postoperative complications - a propensity-score-matched analysis.

Authors:  Kenneth S H Chok; Millies M Y Chan; Wing Chiu Dai; Albert C Y Chan; Tan To Cheung; Tiffany C L Wong; Wong Hoi She; Chung Mau Lo
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

View more
  3 in total

1.  Infection with a human-derived enteroinvasive Escherichia coli strain altered intestinal barrier function in guinea pigs.

Authors:  Jian-Jun Liu; Juan-Juan Qiu; Xiu Shan; Xue-Qi Shang; Fu-Bo Sun; Ju-Ying Jiao; Ayaz Ahmed; Yi Xin; Dong Shang
Journal:  Int Microbiol       Date:  2022-06-20       Impact factor: 3.097

2.  A novel prognostic model for malignant patients with Gram-negative bacteremia based on real-world research.

Authors:  Sujiao Ni; Pingyao Xu; Kaijiong Zhang; Haiming Zou; Huaichao Luo; Chang Liu; Yuping Li; Yan Li; Dongsheng Wang; Renfei Zhang; Ruiling Zu
Journal:  Sci Rep       Date:  2022-07-08       Impact factor: 4.996

Review 3.  The path from big data analytics capabilities to value in hospitals: a scoping review.

Authors:  Pierre-Yves Brossard; Etienne Minvielle; Claude Sicotte
Journal:  BMC Health Serv Res       Date:  2022-01-31       Impact factor: 2.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.